Introduction
Tubulointerstitial fibrosis is characterized by excess accumulation of extracellular matrix (ECM) in the renal interstitium. As the extent of fibrosis is an important predictor of outcome in patients with renal diseases, much work has been done to analyze the mechanisms that control the balance between synthesis and degradation of ECM, particularly the metalloproteinase (MMP)/ tissue inhibitor of MMP system [1, 2] . Given their capacity to degrade ECM, MMPs were originally believed to be beneficial and protective against renal fibrogenesis; however, more recent information suggests that MMP-2 and MMP-9 disrupt tubular basement membrane, promote epithelial-mesenchymal transition (EMT), and lead to interstitial fibrosis [3, 4] . Figure 1A shows Masson's trichrome staining of renal biopsies from two patients with IgA nephropathy. Although the extent of the fibrosis is similar, the prognostic outcomes of the two cases were quite different: whereas in case A, renal function remained stable after 8 years of follow-up, case B declined to renal failure within 2 years. Notably, when biopsies from the two patients were immunostained for fibroblast-specific protein-1 (FSP1), more accumulation of FSP1 + cells was detected in the biopsy from case B, but not case A (Fig.  1B) . This finding is particularly noteworthy because it suggests that whether fibrosis is detrimental or not does not depend solely on its extent, but also on the presence of other key cellular components.
Cells infiltrating the renal interstitium have long been believed to play a major role in the initiation and progression of tubulointerstitial fibrosis. This is because the degree to which a number of cell types, macrophages, lymphocytes, and fibroblasts accumulate in the renal interstitium parallels the extent of fibrogenesis. Moreover, it has been difficult to distinguish harmful cells from beneficial cells using standard histopathological techniques. Recent advances in molecular technol-ogy, however, now enable one to analyze different cell types separately, and activated fibroblasts have been identified as the principal effector mediating tubulointerstitial fibrosis [5] . By contrast, macrophages may not always be harmful, as their phagocytosis of ECM fragments may sometimes be beneficial [6] .
Until recently, it has been difficult to answer the following simple questions: (1) What are fibroblasts?
(2) Do fibroblasts play a principal role in the progression of fibrosis in vivo? (3) Where do fibroblasts come from? Since the identification of FSP1 as a specific marker of tissue fibroblasts, they have been found to originate or multiply from a variety of sources, including local EMT, the bone marrow, resident fibroblasts or myofibroblasts [7] . Moreover, emerging evidence has recently shown that fibroblasts derived from EMT play a critical role in tubulointerstitial fibrosis [7, 8] . With that as background, the present review focuses on a newly proposed mechanism of tubulointerstitial fibrosis, one that emphasizes the roles of EMT and cellular activation.
Epithelial-mesenchymal transition
Although tissue fibroblasts are quiescent and sparsely distributed in the normal renal interstitium, under pathological conditions they can rapidly proliferate, produce interstitial collagens, and contribute to the progression of tissue fibrosis. One of the most plausible explanations for the replenishment of fibroblasts during fibrogenesis is EMT. In fact, we recently provided direct evidence that the pathological stress of tissue fibrosis leads to a large fraction of interstitial fibroblasts being derived from tubular epithelial cells [7] . As shown in Table 1 , numerous molecules associated with EMT are now known. Such an accumulation of EMT-derived fibroblasts associated with tubular decondensation and atrophy is considered to be a key determinant of renal fibrosis during chronic injury.
EMT is composed of two distinct steps: the loss of epithelial cell adhesions enabling cells to dissociate from their epithelial sheets and basement membrane, and enhanced cell motility allowing them to infiltrate the interstitium or fall into tubular fluid to be washed downstream. Although growth factors such as transforming growth factor-b (TGFb), epidermal growth factor [9] , and fibroblast growth factor-2 [10] , as well as reactive oxygen species [11] , are known to facilitate EMT, their underlying signaling pathways are just now coming into focus [12 . . ].
Among the things known about the initiation of EMT is that Snail, a zinc-finger transcription factor, binds directly to E-boxes in the promoter regions of E-cadherin, claudin and occuludin, thereby repressing their expression [13, 14] . Snail is induced by the nuclear import of lymphoid enhancer factor co-activated by b-catenin or Smad3 [15] . It is likely that Snail transcription, among others [12 . . ], plays a critical role in the first steps of EMT by repressing genes encoding adherens and tight junction adhesion molecules. Disruption of the tubular basement membrane (TBM) is also a complementary step in the initiation of EMT. As collagen type IV, the main constituent of the TBM, is a specific substrate of MMP-2 and MMP-9, it would seem likely these enzymes are also involved in initiating EMT. Consistent with that notion, TGFb stimulates the synthesis of both MMP-2 and its activator protease, MMP-14, in a renal tubular epithelial cell line, and the two enzymes colocalize at sites of basal lamina disruption in a remnant kidney model [4] . In addition, tissue plasminogen activator induces MMP-9 gene expression in renal fibroblasts and the subsequent secretion of MMP-9 protein. There is a marked decrease in MMP-9 expression in the obstructed kidneys of tissue plasminogen activator-null mice, which leads to dramatic preservation of the structural and functional integrity of the TBM [3]. Thus, MMP-2 (in conjunction with MMP-14) and MMP-9 may both contribute to the initiation of EMT through degradation of the TBM.
Because TGFb is the principal factor that promotes EMT in vitro, much study has focused on the signaling pathways involved in TGFb-induced EMT. TGFb induces Smad2 phosphorylation in a tubular epithelial cell line, and that overexpression of an inhibitory Smad protein, Smad7, markedly inhibits TGFb-induced Smad2 activation, thereby preventing EMT and collagen synthesis [16,17 . ]. This suggests that Smad signaling can regulate EMT both positively and negatively. Bone morphogenic protein-7 (BMP7) also inhibits TGFbinduced EMT, and one recent report provides evidence for a direct BMP7 and Smad-dependent counteraction of TGFb; BMP7 reversed TGFb-induced EMT through a Smad-dependent re-induction of E-cadherin expression [18 . . ]. Indeed, systemic administration of recombinant human BMP7 leads to the repair of severely damaged renal tubular epithelial cells and reversed renal fibrosis. An evaluation of the clinical effects of recombinant human BMP7 on chronic renal injury in humans may be warranted.
TGFb also induces Smad-dependent expression of integrin-linked kinase in tubular epithelial cells. Integrin-linked kinase is an intracellular serine/threonine protein kinase that interacts with the cytoplasmic domains of b-integrins and numerous other cytoskeleton-associated proteins and is involved in the regulation of such integrin-mediated processes as cell adhesion, changes in cell shape and ECM deposition [19, 20] . Forced expression of integrin-linked kinase in human proximal tubular epithelial cells suppresses expression of E-cadherin and induces fibronectin and MMP-2. Notably, a dominant-negative integrin-linked kinase mutant largely abrogated TGFb-initiated EMT, suggesting that integrin-linked kinase also plays a critical role in EMT [21 . ]. Hepatocyte growth factor, a well-known antifibrotic factor, was also shown to have an anti-fibrotic effect through the inhibition of integrin-linked kinase and blockade of EMT [22, 23] .
Finally, Rho, a member of the small GTPase family of proteins, may be yet another key mediator of EMT [12 . . ]. Rho increases stress fiber formation and myosin light chain phosphorylation, which in turn leads to increased cell contractility [24] . TGFb induces detectable increases in the levels of active Rho in LLC-PK1 cells, while expression of a dominant negative form of Rho kinase attenuates TGFb-induced F-actin reorganization, indicating the Rho/Rho kinase pathway to be essential for TGFb-induced cytoskeletal remodeling. In addition, Rho strongly stimulates the aSMA promoter in LLC cells, whereas two inhibitory Rho constructs prevent TGFb-induced promoter activation [25] .
Cellular function in the progression of tubulointerstitial fibrosis
Because fibroblasts are capable of very rapid proliferation and actively produce fibronectin and a variety of collagens (particularly types I and III), they have long been believed to play a principal role in the initiation and progression of tubulointerstitial fibrosis. In fact, however, the extent to which fibrosis reflects fibroblast number has until recently been unclear because there were no specific markers for tissue fibroblasts. It was Strutz et al. [26] who first cloned FSP1 and demonstrated that cells identified by FSP1 expression rapidly increase in number during experimental fibrosis. The proximity of these fibroblasts to the ECM further suggested they were responsible for the generation of new matrix proteins [7] . We subsequently reported that experimental fibrogenesis could be attenuated by selective elimination of tissue fibroblasts using a herpes virus thymidine kinase transgene under the control of the FSP1 promoter [5]. That report provided the first direct evidence that fibroblasts play a crucial role in the progression of fibrosis in vivo.
Interstitial fibroblasts are much more heterogeneous than expected. Indeed, renal fibroblasts include interstitial resident fibroblasts, circulating fibrocytes, EMTderived fibroblasts, bone marrow-derived fibroblasts, and myofibroblasts expressing aSMA [7, 27] . Of these, the actions of the aSMA + , FSP1 + myofibroblasts are less evident than those of aSMA 7 , FSP1 + cells. For instance, in mice with polycystic disease, activated fibroblasts identified by their expression of the collagen-specific stress protein HSP47 were mostly FSP1 + and aSMA 7 [28] . In TGFb transgenic mice, however, activated fibroblasts did express aSMA [29] . It would be interesting to carry out similar analyses of the interstitial fibrosis that accompanies human glomerulonephritis, as the results might clarify the dynamics of interstitial fibroblast activation in humans.
Because macrophages release several factors that contribute to the induction of fibrosis, and the number of infiltrating macrophages correlates with its extent, macrophages have long been thought to contribute to its progression of renal fibrosis. This hypothesis has been further supported by the studies carried out in animals depleted of macrophages or in animals lacking or inhibiting genes that encode proteins important for macrophage recruitment [30] [31] [32] [33] [34] . By contrast, Nishida et al.
[6] recently reported the unexpected finding that infiltrating macrophages can have anti-fibrotic effects in renal fibrosis. They used wild-type mice that were transplanted after lethal irradiation with bone marrow from mice lacking the angiotensin II type 1 receptor gene. Fourteen days after the induction of unilateral ureteral obstruction, kidneys from mice with angiotensin II type 1 receptor-deficient bone marrow showed more severe renal fibrosis and fewer infiltrating macrophages than did those from untreated wild-type mice. Analysis of macrophage function revealed that migration and phagocytic activity were diminished in those lacking the angiotensin II type 1 receptor gene, suggesting that macrophages attenuate renal fibrosis through phagocytic clearance of ECM fragments and apoptotic cells. The urokinase cellular receptor (uPAR) is known be involved in cell adhesion and migration and in angiogenesis. In uPAR 7/7 mice, which show significantly more severe renal fibrosis than control animals, numbers of interstitial macrophages are significantly reduced, while those of aSMA + cells and CD34 + endothelial cells are significantly increased [35, 36] . This again suggests that macrophages are not mandatory for the development of tubulointerstitial fibrosis and may even mitigate it.
The degree of renal interstitial fibrosis is also well correlated with the number of infiltrating tryptasepositive mast cells, which play a role in the proliferation of renal interstitial fibroblasts and production of ECM and thus contribute to the development of renal interstitial fibrosis [37] . The capacity of mast cell tryptase to elicit fibroblast proliferation is dependent on cyclooxygenase-2 and prostaglandin synthesis [38] . Furthermore, the expression of several mast cell chemokines, including stem cell factor, IL-8 and TGFb, are increased in 5/6 nephrectomized kidneys, suggesting that mast cells are effectors in tubulointerstitial fibrosis [39] .
Roles of ischemia and hypoxia
One of the most important contributors to the development of tubulointerstitial fibrosis is chronic ischemia. Production of angiotensin II and inhibition of production of nitric oxide underlie chronic vasoconstriction, which may contribute to tissue ischemia and hypoxia [40] . In that regard, Bohle et al.
[1] observed that there is often a loss of peritubular capillaries in areas of tubulointerstitial fibrosis, a finding that was confirmed by a recent study using aminopeptidase P as a specific marker of blood capillaries [41] . Focal reduction of capillary blood flow leading to starvation of tubuli may underlie tubular atrophy and loss. Under these conditions, the remaining tubules are subject to functional hypermetabolism with increased oxygen consumption, which in turn creates an even more severely hypoxic environment in the renal interstitium. In vitro, such hypoxia stimulates fibroblast proliferation and ECM production by tubular epithelial cells [42] .
Renin-angiotensin system
Recent reports have shown that the intrarenal reninangiotensin system is activated in human membranous nephropathy, type 2 diabetic nephropathy, and IgA nephropathy [43, 44] . Local levels of angiotensin converting enzyme (ACE) are increased in the proximal tubules and in cells infiltrating the tubulointerstitium of injured kidneys in both diabetic and membranous nephropathies. Consistent with those findings, blockade of ACE has been shown to exert an anti-fibrotic effect in a number of basic and clinical investigations, confirming the renin-angiotensin system plays a central role in the progression of renal fibrosis. Angiotensin II, the major vasoactive peptide in the renin-angiotensin system, is also a key mediator of inflammation, inducing expression of a wide range of cytokines and chemokines, including TGFb, osteopontin, tumor necrosis factor-a, SPARC, IL-6, monocyte chemoattractant protein-1 and RANTES [45, 46] . Angiotensin II also induces tissue inhibitor of MMP-1 expression in human proximal tubular epithelial cells through the STAT signaling pathway and may stimulate formation of superoxide anions (O 2 7 ) in cultured LLC-PK1 and cultured mouse proximal tubule cells [47] .
Angiotensin II induces synthesis of TGFb in tubular epithelial cells. As TGFb is the most potent of profibrotic cytokines, the fibrotic effect of angiotensin II may be TGFb-dependent. In that regard, integrin a5b6, a heterodimeric matrix receptor expressed in epithelia, is known to bind to and activate latent TGFb. With that in mind, Ma et al. [48] used b6 integrin-null (b6 7/7 ) mice to demonstrate a TGFb-independent, plasminogen activator inhibitor-1-dependent pathway leading to induction of fibrosis via angiotensin. They found that infusion with angiotensin II into b6 7/7 unilateral ureteral obstruction mice significantly increased the collagen content, despite lower levels of active TGFb and Smad; the response was linked to local plasminogen activator inhibitor-1 expression. ACE inhibitors reduce the progression of interstitial fibrosis in several animal models, as well as in human glomerulonephritis. In addition to their effects on angiotensin II formation, ACE inhibitors increase bradykinin concentrations, and Schanstra et al. [49] showed that mice lacking the bradykinin B2-receptor (B2 7/7 ) were more likely than control animals to develop tubulointerstitial fibrosis. Bradykinin increases plasminogen activators in proximal tubular cells, induces ECM degradation and has anti-fibrotic effects. By contrast, a recent report by the same group showed no difference in the degree of tubulointerstitial fibrosis between ACE inhibitor-treated B2 +/+ and B2 7/7 mice, making it unclear whether or not bradykinin actually exerts this anti-fibrotic effect [50] .
Conclusion
In this brief review of recent papers several issues have come to light. In the early stages of renal fibrosis, fibroblasts and tubular epithelial cells activated by the renin-angiotensin system play an important role in the progression of tubulointerstitial fibrosis. Later, with the destruction of TBM, EMT-derived fibroblasts accelerate the fibrosis, ultimately leading to end-stage renal failure. As components of the mechanism underlying tubulointerstitial fibrosis and the signaling pathways leading to EMT have been identified, so have factors that efficiently antagonize renal fibrosis, particularly BMP7 and hepatocyte growth factor. In combination with ACE inhibitors, these newly identified factors may offer new therapeutic strategies aimed at inhibiting the progression of renal failure and thus reducing the number of patients suffering from end-stage renal disease.
